Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to make an assessment of the (a) adequacy of the requirement for UK-produced phages to be manufactured under good manufacturing practice and (b) potential impact of this requirement on patient access to treatment.

In the March 2024 response to the Science, Innovation and Technology Committee’s report on bacteriophages, the Government acknowledged the challenges of requiring United Kingdom-produced phages to meet Good Manufacturing Practice (GMP) standards, which is essential for clinical use.

To address this, the Government committed to exploring the case for a dedicated GMP facility to support phage innovators, working with key stakeholders, including funders and research organisations, to strengthen the UK’s phage manufacturing capabilities and thereby improve patient access to these therapies.